[1. Facchetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cell neoplasm in: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Edition. International Agency for Research on Cancer. Lyon 2008;145-7.]Search in Google Scholar
[2. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol. 2007;136(4):539-48. DOI: 10.1111/j.1365-2141.2006.06458.x10.1111/j.1365-2141.2006.06458.x17367408]Search in Google Scholar
[3. Lúcio P, Parreira A, Orfao A. CD123hi dendritic cell lymphoma: an unusual case of non-Hodgkin lymphoma. Ann Intern Med. 1999;131(7):549-50. DOI: 10.7326/0003-4819-131-7-199910050-0003510.7326/0003-4819-131-7-199910050-0003510507983]Search in Google Scholar
[4. Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210-7. DOI: 10.1182/blood.V97.10.321010.1182/blood.V97.10.3210]Search in Google Scholar
[5. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS, et al. Blastic plasmocytoid dendritic cell neoplasm in children: diagnostic feature and clinical presentations. Haematologica. 2010;95(11):1873-9. DOI: 10.3324/haematol.2010.02617910.3324/haematol.2010.026179296690920663945]Search in Google Scholar
[6. Herling M, Jones D. CD4+/CD56+ Hematodermic Tumor. The features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007;127(5):687-700. DOI: 10.1309/FY6PK436NBK0RYD410.1309/FY6PK436NBK0RYD417439829]Search in Google Scholar
[7. Facchetti F, Ungari M, Marocolo D, Lonardi S, Vermi W. Blastic plasmocytoid dendritic cell neoplasm. Hematology Meeting Reports. 2009;3(3):1-3.]Search in Google Scholar
[8. Jacob MC, Chaperot L, Mossuz P, Feuillard J, Valensi F, Leroux D, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88(8):941-55.]Search in Google Scholar
[9. Rauh MJ, Rahman F, Good D, Silverman J, Brennan MK, Dimov N, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: Case series and literature review. Leuk Res. 2012;36(1):81-6. DOI: 10.1016/j.leukres. 2011.07.033]Search in Google Scholar
[10. Feuillard J, Jacob MC, Valensi F, Maynadié M, Gressin R, Chaperot L, et al. Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood. 2002;99(5):1556-63. DOI: 10.1182/blood.V99.5.155610.1182/blood.V99.5.1556]Search in Google Scholar
[11. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75-87. DOI: 10.1097/PAS. 0b013e3181c5e26b]Search in Google Scholar
[12. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662-75. DOI: 10.1309/GJWNPD8HU5MAJ83710.1309/GJWNPD8HU5MAJ837]Search in Google Scholar
[13. Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, et al for GOELAMS and GEIL study. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-36. DOI: 10.1111/j.1365-2141.2009.07679.x10.1111/j.1365-2141.2009.07679.x19388928]Search in Google Scholar
[14. Pangano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al for GIMEMA-ALWP* (Gruppo Italiano Malattie EMatologiche dell’Adulto, Acute Leukemia Working Party). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-46. DOI: 10.3324/haematol.2012.07264510.3324/haematol.2012.072645356143123065521]Search in Google Scholar
[15. Reimer P, Rüdiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637-46. DOI: 10.1038/ sj.bmt.170421510.1038/sj.bmt.1704215709194713130309]Search in Google Scholar
[16. Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM, et al. Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011;17(8):1250-4. DOI: 10.1016/j.bbmt.2010.12.70610.1016/j.bbmt.2010.12.70621215813]Search in Google Scholar
[17. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005;105(3):1256-64. DOI: 10.1182/ blood-2004-06-241610.1182/blood-2004-06-241615388576]Search in Google Scholar
[18. Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, et al. Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica. 2004;89(1):58-69.]Search in Google Scholar
[19. Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ. CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti-CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom. 2009;76(4):237-48. DOI: 10.1002/ cyto.b.2046910.1002/cyto.b.2046919382197]Search in Google Scholar
[20. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H,et al. NK-cell Tumor Study Group - Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010;21(5):1032-40. DOI: 10.1093/annonc/mdp41810.1093/annonc/mdp41819850638]Search in Google Scholar
[21. Di Bona E, Sartori E, Zambello R, Guercini N, Medeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica. 2002;87(3):250-6.]Search in Google Scholar
[22. Béné MC. Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias! Haematologica. 2009;94(7):891-3. DOI: 10.3324/haematol. 2009.007799]Search in Google Scholar
[23. Dongen JJM, Lhermitte L, Bottcher S, Almeida J, van der Velden VHJ, Flores-Montero J, et al. Euroflow antibody panels for standardized n-dimensional flowcytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908-75. DOI: 10.1038/leu.2012.120 10.1038/leu.2012.120343741022552007]Search in Google Scholar